Biophoton Therapy for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a new treatment, biophoton therapy, can help manage type 2 diabetes. Participants will receive either active biophoton therapy or a placebo device for a short period to assess its effectiveness. The trial is double-blind, so neither participants nor researchers know who receives the actual treatment during the initial phase. This study may suit adults diagnosed with type 2 diabetes who do not heavily use Tesla BioHealing devices. Participants should also be fluent in English to follow trial instructions. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research in diabetes management.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.
What prior data suggests that biophoton therapy is safe for treating diabetes?
Research has shown that biophoton therapy is usually safe and well-tolerated. In one study, after six weeks of strong biophoton therapy, patients had healthier blood cells without negative effects. Another study found that it improved blood sugar levels and oxygen concentration, again with no major safety issues. While these studies show positive results, individual experiences can vary. Overall, current evidence suggests that biophoton therapy is safe for most people.12345
Why are researchers excited about this trial?
Researchers are excited about Biophoton Therapy for Type 2 Diabetes because it offers a novel approach by using light to potentially influence cellular processes. Unlike typical treatments that focus on medications like metformin or insulin to control blood sugar levels, Biophoton Therapy aims to use biophotons, which are light particles, to improve insulin sensitivity and glucose metabolism. This non-invasive technique could provide a unique alternative for managing diabetes, with the potential to reduce reliance on medications and improve overall quality of life for patients.
What evidence suggests that biophoton therapy might be an effective treatment for diabetes?
Research has shown that biophoton therapy might help manage Type 2 diabetes by using light to affect cellular function. One study found that this therapy was about 50% effective in lowering blood sugar levels during the first two weeks. Another study demonstrated that six weeks of strong biophoton therapy improved the health and energy of blood cells in a person with diabetes. These findings suggest that biophoton therapy could help control blood sugar and improve cell health in people with diabetes. While more research is needed, these early results are promising for better diabetes management. Participants in this trial will receive either the biophoton therapy or a placebo device that does not emit biophotons, allowing for a comparison of their effects.12346
Are You a Good Fit for This Trial?
This trial is for individuals with Type 2 Diabetes who are interested in trying a new treatment called biophoton therapy using Tesla BioHealing Biophoton Generators. Participants will be randomly assigned to either the treatment or control group and must agree to follow study procedures, including signing an informed consent form.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Randomization
Participants are randomly assigned to either the treatment or control group for the initial 4-week period
Treatment
Participants in the treatment group receive active biophoton therapy for 8 weeks, while the control group receives placebo for 4 weeks followed by active treatment for 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Biophoton Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
First Institute of All Medicines
Lead Sponsor